Neuromind Pro Ingredients: The Ten Names on the Label

What cells spend to turn carbohydrate into usable energy, and nerve tissue is an expensive customer. The cognitive benefit tracks a shortfall rather than a surplus: a 2025 systematic review found lower thiamine alongside poorer attention and memory in alcohol use disorder, while Cochrane found too little to say in Alzheimer's disease. No upper intake has been set for thiamine, so 6 mg is a small figure wearing a large percentage.

A cofactor dozens of enzymes borrow, including the ones that finish dopamine, serotonin and noradrenaline. The machinery is real; what the trials add is that topping it up in people never short moved nothing measurable in the Cochrane review of B6 and cognition. It is also the one row carrying a ceiling: EFSA put the adult tolerable upper intake at 12 mg a day, so one capsule uses seven-tenths of a day's headroom.

The row worth a blood test rather than a guess. Absorption falls with age and with long-running metformin or acid-suppressing medicine, and a shortfall shows up in thinking, balance and mood. Correct it and the picture improves. Add it to somebody already replete and the trials fall silent, which is what a meta-analysis of 6,276 participants reported across every cognitive subdomain. 24 mcg is generous, safe, and worth what your starting point makes it worth.

The compound most likely to produce something a first-time user can feel, and the one with the deepest human record. It occupies adenosine receptors, holding off the drift toward drowsiness. The major review puts the useful window between roughly 40 mg and 300 mg, clearest above about 200 mg, and up to 400 mg a day is without adverse effect in healthy adults per a systematic review of caffeine safety.

An amino acid you already eat in any protein, and the starting block the body works up into dopamine and noradrenaline. Its trials are specific about when that matters: the review of the tyrosine literature finds an effect while those transmitters are drained by cold, noise, sleep loss or acute pressure, and little outside it. Cadets on a combat course improved on 2 g a day, and one trial found the effect size tracked a dopamine receptor genotype. Every dose there is written in grams.

A purine alkaloid from kucha tea, close enough to caffeine in shape to reach some of the same receptors without behaving identically. What gets reported is energy rather than recall: volunteers in the cognition and mood trial rated themselves higher on energy and lower on lethargy than on caffeine or placebo. Eight weeks at 200 to 300 mg a day moved no clinical marker and produced no habituation, the reverse of the claim usually attached to it.

Cocoa's own methylxanthine, and much the mildest of the three stimulant compounds here. The largest human study ran 250, 500 and 1,000 mg and found thin subjective effects at the bottom and worse mood with a quicker pulse at the top. An older head-to-head against caffeine had 560 mg of theobromine failing to match 178 mg of caffeine on energy and alertness. Its role is as caffeine's companion at chocolate-like amounts.

The best cognitive record on this label, and much the longest fuse. The meta-analysis set twelve weeks as its entry requirement, and what moved inside that window was speed of attention rather than recall. A twelve-week randomised trial in older adults ran 300 mg a day of standardised extract, though a 2025 trial in 101 healthy adults separated from placebo on nothing. Stomach discomfort is its commonest complaint.

An arctic root studied for tiredness and for how heavy effort feels, rather than for memory. A systematic review of eleven placebo-controlled trials reported possible benefit and named its own weakness in the same breath: individual studies have rarely been repeated independently. The amounts are specific and large. The stress-related fatigue trial used 576 mg a day of standardised extract and an open-label burnout study used 400 mg.

The outlier, and the reason the blend line is worth thinking about at all. Huperzine-A is a reversible acetylcholinesterase inhibitor: it slows the enzyme that clears acetylcholine, the lever prescription dementia medicines pull. It is active in micrograms, so its studied amount is the only one here a 151 mg blend could hold several times over. The efficacy record is thinner than the reputation: the best-conducted Western trial gave 200 mcg twice daily for sixteen weeks without shifting its primary outcome, and a later meta-analysis judged most trials at high risk of bias.